Mouse model of chronic heart failure and coronary atherosclerosis regression
An animal model has been developed where the animals can survive myocardial infarctions caused by diet-induced coronary atherosclerosis, and live with chronic heart failure. This animal model is a result of reduced activity of scavenger receptor class BI (SR-BI) and ApoE and the inducible activity of the Mx1-Cre gene. In a preferred embodiment, the model is a result of crossbreeding two transgenic mouse lines: a knockout of SR-BI (SRBI −/− ) and an impaired ApoE expressor (Apoe h/h ) to generate a strain referred to as Apoe h/h SRB1 −/− mice, which is then crossbred to mice that carry the inducible Mx1-Cre transgene. The Apoe h/h SRB1 −/− mouse model is genetically modified, enabling the offspring to rapidly and permanently lower their high blood cholesterol levels caused by dietary challenge. The ability to rapidly and permanently lower blood cholesterol levels in these mice stops and may cause the regression of occlusive coronary atherosclerosis restoring blood flow to the heart, allowing the mice to survive from myocardial infarction and live with chronic heart failure.
1. A transgenic mouse whose genome comprises:
(a) a homozygous disruption of the endogenous Scavenger Receptor class B, type I gene (SR-B1 −/− );
(b) a homozygous Arg-61 allelic variant of mouse apolipoprotein E gene (ApoE h/h ) having inserted at each allele a floxed neomycin cassette; and
(c) an inducible Mx1-Cre transgene,
wherein feeding the mouse a cholesterol enriched diet results in the induction of myocardial infarction and wherein following said myocardial infarction, normal ApoE levels can be restored by spatially and temporally regulating expression of the ApoE gene by inducing the Mx1-Cre gene and allowing the transgenic mouse to rapidly reduce its blood cholesterol and live with chronic heart failure while displaying myocardial infarctions and enlarged ventricles.
2. The transgenic mouse of claim 1 , wherein the mouse is sensitive to diet-induced coronary atherosclerosis and develops fatal myocardial infarctions within 35 days of initiating a high cholesterol diet prior to said induction of Mx1-Cre.
3. A method for screening a compound for having an effect on disorders selected from the group consisting of atherosclerosis, and chronic heart failure comprising
(a) administering a compound that may have an effect on chronic heart failure or arthrosclerosis to the transgenic mouse of claim 1 exhibiting chronic heart failure with myocardial infarctions and enlarged ventricles, and
(b) determining the effect of the compound on said disorder in the mouse relative to a control mouse not treated with the compound.
4. A method for making the mouse of claim 1 for screening for compounds affecting the symptoms of a disorder selected from the group consisting of cardiac atherosclerosis and chronic heart failure, said method comprising
(a) crossing a transgenic mouse whose genome comprises a homozygous Arg-61 allelic variant of mouse ApoE (ApoE h/h ) gene having inserted at each allele a floxed neomycin cassette with a transgenic mouse whose genome comprises an inducible Mx1-Cre transgene to produce a ApoE h/h /Mx1-Cre mouse;
(b) crossing a transgenic mouse whose genome comprises a homozygous disruption of the endogenous SR-B1 gene (SR-B1 −/− ) with the ApoE h/h /Mx1-Cre mouse to produce an ApoE h/h /SR-B1 −/− Mx1-Cre mouse,
wherein feeding the transgenic ApoE h/h /SR-B1 −/− Mx1-Cre mouse a cholesterol enriched diet results in the induction of myocardial infarction and wherein following said myocardial infarction, normal ApoE levels can be restored by spatially and temporally regulating expression of the ApoE gene by inducing the Mx1-Cre gene and allowing the transgenic mouse to rapidly reduce its blood cholesterol and live with chronic heart failure while displaying myocardial infarctions and enlarged ventricles.